(goserelin acetate implant)
ZOLADEX® (goserelin acetate implant), contains a potent synthetic decapeptide analogue of luteinizing hormone-releasing hormone (LHRH), also known as a gonado-tropin releasing hormone (GnRH) agonist analogue.
ZOLADEX® is indicated for the following:
Prostatic Carcinoma: ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate.
Stage B2-C Prostatic Carcinoma: ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.
Endometriosis: ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months.
Advanced Breast Cancer: ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women.
The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial. (See CLINICAL PHARMACOLOGY.)
Endometrial Thinning: ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.
The automatic safety feature of the syringe aids in the prevention of needlestick injury.
Published Studies Related to Zoladex (Goserelin)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for
premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. 
goserelin for early breast cancer in the neoadjuvant setting... INTERPRETATION: Given its favourable risk-benefit profile, the combination of
Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. [2011.04]
This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (Zoladex(TM)) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study.In terms of E(2) suppression, 3-monthly goserelin 10.8 mg was non-inferior to monthly goserelin 3.6 mg in pre-menopausal women with ER+ breast cancer.
Randomized comparison of goserelin versus suction curettage prior to Thermachoice II balloon endometrial ablation: one-year results. [2010.10]
OBJECTIVES: To evaluate the clinical outcomes following the use of goserelin and suction curettage prior to ThermaChoice II balloon endometrial ablation to treat menorrhagia... CONCLUSION: At one year after ThermaChoice II treatment, 88.5% of women had normal menstrual bleeding or less. There was a non-significant trend (a lower Higham score) towards superiority of goserelin therapy before ablation compared with curettage.
Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. [2009.03.04]
BACKGROUND: Systematic reviews have found that luteinizing hormone-releasing hormone (LHRH) agonists are effective in treating premenopausal women with early breast cancer... CONCLUSIONS: Two years of goserelin treatment was as effective as 2 years of tamoxifen treatment 15 years after starting therapy. In women who did not take tamoxifen, there was a large benefit of goserelin treatment on survival and recurrence, and in women who did take tamoxifen, there was a marginal potential benefit on these outcomes when goserelin was added.
A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. [2007.11]
OBJECTIVE: To compare the mechanism of action of raloxifene and gosereline induced shrinkage of leiomyomas via estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically... CONCLUSION: Raloxifene was as effective as gosereline in reducing leiomyoma volumes. Decreased PR expression may be a mechanism for tumor growth reduction in raloxifene treatment. In both treatment modalities, the mechanism of shrinkage of leiomyomas could not be increased apoptosis mediated by bcl-2 and p53 expression and should be investigated by further studies.
Clinical Trials Related to Zoladex (Goserelin)
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer [Recruiting]
The purpose of this study is to assess the efficacy of goserelin plus fulvestrant 500mg
comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and
perimenopausal HR+ advanced breast cancer.
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women [Recruiting]
Fulvestrant is an ER antagonist with no agonist effects, which binds, blocks and degrades
the ER. Fulvestrant is comparable to third-generation aromatase inhibitors in terms of
efficacy and tolerability for patients who have progressed on prior tamoxifen therapy and
past studies have found all three-third-generation AIs to be at least as good as tamoxifen
in first-line metastatic therapy in postmenopausal women. Fulvestrant has been studied
little in premenopausal women despite of its attractive mechanism of actions. The clinical
effectiveness of fulvestrant as a treatment for advanced breast cancer has previously been
demonstrated at the standard dose (AD; 250 mg/mo) in several phase III clinical trials in
postmenopausal women. However, there is evidence to suggest that doses of fulvestrant higher
than 250 mg may have greater pharmacodynamic activity against the ER pathway. Moreover,
dose-dependent clinical activity has been observed for fulvestrant. The activity of a
fulvestrant high-dose (HD; 500 mg/mo) regimen has been investigated in two recent studies. A
pilot Japanese study showed fulvestrant HD to have clinical activity in the treatment of
advanced or recurrent breast cancer, to be well tolerated, and to result in plasma levels
approximately double those seen with fulvestrant low-dose. Subsequently, a neoadjuvant study
comparing fulvestrant low-dose and high-dose reported that significantly greater Ki67 and ER
downregulation was achieved with the high-dose compared with the low-dose regimen and that
both doses were well tolerated. A recent randomized trial also showed superior outcome of
high-dose fulvestrant than AI.
Based on this rationale, we introduced high-dose fulvestrant with LHRH agonist as a
randomized trial comparing with AI plus LHRH agonist and LHRH alone in premenopausal
metastatic breast cancer patients who failed to tamoxifen treatment.
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer [Recruiting]
This phase II trial studies how well Akt inhibitor MK-2206 (MK-2206) and anastrozole with or
without goserelin acetate works in treating patients with stage II-III breast cancer.
MK-2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using
anastrozole and goserelin acetate may fight breast cancer by blocking the use of estrogen by
the tumor cells. Giving MK-2206, anastrozole, and goserelin acetate together may kill more
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer [Terminated]
- To determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian
function in premenopausal women undergoing neoadjuvant and/or adjuvant chemotherapy for
primary invasive breast cancer by documenting persistence or resumption of regular
- To determine the incidence of pregnancy and the effect for participants' quality of
life (QOL) after chemotherapy.
- To determine the overall survival and disease-free survival times of study
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC [Completed]
Primary objective is to evaluate the response rates and clinical benefits of letrozole +
goserelin in premenopausal patients versus letrozole alone in postmenopausal patients with
metastatic breast cancer as first line hormonal therapy
Reports of Suspected Zoladex (Goserelin) Side Effects
Prostate Cancer (17),
Hot Flush (14),
Prostatic Specific Antigen Increased (8),
Hepatic Function Abnormal (7),
Wrong Technique in Drug Usage Process (7),
Disease Progression (7),
Prostate Cancer Metastatic (7), more >>